Table 2.
Peri- and postoperative outcomes of HoLEP by study
| Variable | Fuschi et al. [11••] | Kim et al. [7] | Umari et al. [10] | Zhang et al. [6] |
|---|---|---|---|---|
| Cohort size (n) | 42 | 26 | 45 | 600 |
| Length of follow-up (months) | 3 mo | 6 mo | 5 mo | - |
| Operative time (minutes) | 134.32 | 140.0 | 105 | 103** |
| Qmax (mL/sec) |
Pre: 7.05 Post: 20.01 |
Δ = 13.4 |
Pre: 9 Post: 20 |
- |
| PVR (mL) |
Pre: 130.13 Post: 35.47 |
Δ = 127.2 |
Pre: 100 Post: 0 |
- |
| IPSS |
Pre: 24.15 Post: 8.26 |
Δ = 14.7 |
Pre: 21 Post: 3 |
Pre: 20 Post: - |
| QOL |
Pre: 3.89 Post: 1.71 |
Δ = 2.0 | - | - |
| LOS (days) | 2.24** | 2.5** | 2** | 1.3** |
| LOC (days) | 2.32** | 1.5** | 2** | 0.7** |
| Transfusion rates | - | 0 | 0 | 11/600** |
| Re-catheterization rates | - | 1/26 | 1/45 | 13/600 |
| Cost ($) | - | 809 | - | - |
Qmax maximum flow rate, PVR post-void residual volume, IPSS International Prostate Symptom Score, QOL quality of life (of IPSS-QOL), LOS length of hospital stay, LOC length of catheterization, Pre before surgery, Post after surgery
**Denotes significant difference to comparison cohort. Unreported data is represented by hyphen. Pre-operative and post-operative difference denoted by Δ